Literature DB >> 8876380

Membrane-bound carbonic anhydrase activity in the rat corneal endothelium and retina.

H Terashima1, K Suzuki, K Kato, N Sugai.   

Abstract

Localization of carbonic anhydrase (CA) was investigated in the rat eye by light and electron microscopy, and the inhibitory effects on CA distribution in the rat eye were compared between dorzolamide and acetazolamide. The cobalt sulfide histochemical method was used to study the CA localization. Acidic osmification was carried out for postfixation of the electron microscopic observations. The inhibition of CA activity was examined with different concentrations of acetazolamide and dorzolamide. The cytoplasm, lateral cell membranes and karyoplasm of the corneal endothelium showed CA activity. In the retina, the processes and cell bodies of Müller cells, the tips of the outer segments of the rods, and apical villi and basolateral membranes of the pigment epithelium indicated CA activity. CA activity was inhibited by dorzolamide at lower concentrations than needed for acetazolamide and only the CA activity of the nerve fiber layer remained at 10(-6) M of acetazolamide and 5 x 10(-7) M of dorzolamide. The presence of membrane-bound CA activity was confirmed in the corneal endothelium and Müller cells. CA activity was also demonstrated in the apices of rod outer segments and scleral fibroblasts. The CA inhibition test revealed that dorzolamide was a stronger CA inhibitor than acetazolamide and that the CA activity of the nerve fiber layer was strongest in the rat eye.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876380

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  8 in total

1.  EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.

Authors:  Ehsan Rahimy; Gui-Shuang Ying; Wei Pan; Jason Hsu
Journal:  Retina       Date:  2019-04       Impact factor: 4.256

2.  Bicarbonate activates glycolysis and lactate production in corneal endothelial cells by increased pHi.

Authors:  Shimin Li; Rajalekshmy Shyam; Diego G Ogando; Joseph A Bonanno
Journal:  Exp Eye Res       Date:  2020-08-17       Impact factor: 3.467

3.  Role of carbonic anhydrase IV in corneal endothelial HCO3- transport.

Authors:  Xing Cai Sun; Jinhua Li; Miao Cui; Joseph A Bonanno
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03       Impact factor: 4.799

4.  Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Authors:  Jason Hsu; Samir N Patel; Jeremy D Wolfe; Chirag P Shah; Eric Chen; Thomas L Jenkins; Turner D Wibbelsman; Anthony Obeid; Mikel Mikhail; Sunir J Garg; Allen C Ho; Allen Chiang; Marc J Spirn; James F Vander
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

Review 5.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.

Authors:  Josh O Wallsh; Ron P Gallemore
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

6.  Efficacy of adjuvant topical timolol-dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study.

Authors:  Ahmad Mirshahi; Ramin Tadayoni; Navid Mohsenzadeh; Talieh Saeidi Rezvani; Mojtaba Abrishami
Journal:  J Curr Ophthalmol       Date:  2019-02-10

7.  Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial.

Authors:  Farhad Fazel; Hossein Nikpour; Mohsen Pourazizi
Journal:  Biomed Res Int       Date:  2020-01-16       Impact factor: 3.411

8.  Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy.

Authors:  Gerald Liew; I-Van Ho; Stephen Ong; Bamini Gopinath; Paul Mitchell
Journal:  Transl Vis Sci Technol       Date:  2020-12-04       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.